Shots:

• The Nourianz is now available in the US as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease experiencing motor fluctuations- re-emerge between treatment dose known as “off” episodes
• The FDA’s approval of Nourianz is based clinical study assessing Nourianz vs PBO as adjunctive treatment to levodopa/carbidopa in adult patients with PD experiencing “off” episodes- associated with a decrease in “off” time and an increase in “on” time without troublesome dyskinesia
• Nourianz is an adenosine receptor antagonist- available in 20/40mg tablets and is the only therapy for PD that targets adenosine A2A receptor

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Pharmaceutical Technology